US Senate clarifies status of interchangeable biosimilar exclusivity

Home/Policies & Legislation | Posted 27/05/2022 post-comment0 Post your comment

The United States (US) Senate Health, Education, Labor and Pensions (HELP) Committee released a draft of the Food and Drug Administration (FDA) Safety and Landmark Advancements Act (FDASLA) on 17 May 2022.

Interchangeability V18K30

This draft includes reauthorization of the four FDA user fee programmes, including the Biosimilar User Fee Act (BsUFA III), that are due to expire in 2022. Within this, it also clarifies the status of interchangeable biosimilar exclusivity.

The draft outlines that it will be possible for multiple interchangeable biosimilars to share a period of the first interchangeable exclusivity if they are approved on the same day and otherwise qualify for exclusivity. In addition, FDA can tentatively approve a subsequent interchangeable biosimilar while a first interchangeable product’s exclusivity period is pending.

FDA defines an interchangeable product as a ‘biosimilar that meets additional requirements outlined by the law that allows for the FDA to approve biosimilar and interchangeable medications’. An interchangeable biosimilar can be substituted at the pharmacy level, without the approval of the prescriber (similar to generics) [1].

Once the draft has been finalized, the updated user fee programmes will be in place for a further five years, until 2027.

It has already been announced that there will be US$5 million funding for research proposals under the BsUFA III Regulatory Science Pilot Program [2]. This followed the release of the FDAs Performance Goals Letter for BsUFA III in September 2021 [3], which outlined key provisions including advancing development of interchangeable biosimilars, enhancing inspection-related communications and modernizing facility assessment approaches.

Related articles
FDA publishes final Q&A on biosimilar development and the BPCI Act

Interactive map for interchangeable biosimilars

FDA issues new guidance for biosimilar user fees

Biosimilars and interchangeability

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Nomenclature of biologicals and biosimilars in Peru

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Nomenclature of biologicals and biosimilars in Peru

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

References
1. GaBI Online - Generics and Biosimilars Initiative. FDA releases new information on interchangeable biologicals [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 May 27]. Available from: www.gabionline.net/biosimilars/general/FDA-releases-new-information-on-interchangeable-biologicals
2. GaBI Online - Generics and Biosimilars Initiative. FDA funds regulatory science pilot for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 May 27]. Available from: www.gabionline.net/policies-legislation/fda-funds-regulatory-science-pilot-for-biosimilars
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilar User Fee Act III-performance goals letter published [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 May 27]. Available from: www.gabionline.net/guidelines/biosimilar-user-fee-act-iii-performance-goals-letter-published

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
PDUFA VI: FDA could promote generics competition
47 MD001813
Home/Policies & Legislation Posted 29/07/2022
House bill passes FDA funding fees but conflicts with Senate bill
User Fee V13H23
Home/Policies & Legislation Posted 15/07/2022
Nomenclature of biologicals and biosimilars in Peru
02 AA010638
Home/Policies & Legislation Posted 20/05/2022
United States legislation to improve access to insulin
Insulin 1 V13C03
Home/Policies & Legislation Posted 29/04/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010